{"id":"https://openalex.org/W2747740549","doi":"https://doi.org/10.1182/blood.v128.22.5885.5885","title":"Updated Outcomes of Fludarabine/Melphalan/Bortezomib (Flu/Mel/Vel) Conditioning for Upfront Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma","display_name":"Updated Outcomes of Fludarabine/Melphalan/Bortezomib (Flu/Mel/Vel) Conditioning for Upfront Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma","publication_year":2016,"publication_date":"2016-12-02","ids":{"openalex":"https://openalex.org/W2747740549","doi":"https://doi.org/10.1182/blood.v128.22.5885.5885","mag":"2747740549"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v128.22.5885.5885","doi":"https://doi.org/10.1182/blood.v128.22.5885.5885","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.5885.5885","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5062691289","display_name":"Taiga Nishihori","orcid":"https://orcid.org/0000-0002-2621-7924","observed_orcids":["https://orcid.org/0000-0002-2621-7924"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Taiga Nishihori","raw_affiliation_strings":["Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060783496","display_name":"Claudio Anasetti","orcid":"https://orcid.org/0000-0002-0119-0622","observed_orcids":["https://orcid.org/0000-0002-0119-0622"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Claudio Anasetti","raw_affiliation_strings":["Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077110117","display_name":"Rachid Baz","orcid":"https://orcid.org/0000-0003-4538-4733","observed_orcids":["https://orcid.org/0000-0003-4538-4733"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachid Baz","raw_affiliation_strings":["Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091150651","display_name":"Jose Leonel Ochoa-Bayona","orcid":"https://orcid.org/0009-0004-7587-2214","observed_orcids":["https://orcid.org/0009-0004-7587-2214"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jose L Ochoa-Bayona","raw_affiliation_strings":["Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053572690","display_name":"Kenneth H. Shain","orcid":"https://orcid.org/0000-0003-4178-8888","observed_orcids":["https://orcid.org/0000-0003-4178-8888"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth H. Shain","raw_affiliation_strings":["Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061566528","display_name":"Ryan Hillgruber","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan Hillgruber","raw_affiliation_strings":["Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087799564","display_name":"Melissa Alsina","orcid":"https://orcid.org/0000-0003-4946-823X","observed_orcids":["https://orcid.org/0000-0003-4946-823X"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa Alsina","raw_affiliation_strings":["Department of Blood an Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Blood an Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I3019308854"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.24202553,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"128","issue":"22","first_page":"5885","last_page":"5885"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":0.008299999870359898,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10373","display_name":"Renal Transplantation Outcomes and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2747","display_name":"Transplantation"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/allogeneic-hematopoietic-stem-cell-transplantation","display_name":"allogeneic hematopoietic stem cell transplantation","score":0.9940000176429749},{"id":"https://openalex.org/keywords/upfront-transplantation","display_name":"upfront transplantation","score":0.6510000228881836},{"id":"https://openalex.org/keywords/fludarabine","display_name":"fludarabine","score":0.8140000104904175},{"id":"https://openalex.org/keywords/melphalan","display_name":"melphalan","score":1.0},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9940000176429749},{"id":"https://openalex.org/keywords/conditioning-regimen","display_name":"conditioning regimen","score":0.9229999780654907},{"id":"https://openalex.org/keywords/graft-versus-host-disease-prophylaxis","display_name":"graft-versus-host disease prophylaxis","score":0.8859999775886536},{"id":"https://openalex.org/keywords/tacrolimus","display_name":"tacrolimus","score":0.7900000214576721},{"id":"https://openalex.org/keywords/methotrexate","display_name":"methotrexate","score":0.875},{"id":"https://openalex.org/keywords/graft-versus-myeloma-effect","display_name":"graft-versus-myeloma effect","score":0.75},{"id":"https://openalex.org/keywords/relapse","display_name":"relapse","score":0.4090000092983246},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7210000157356262},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5759999752044678},{"id":"https://openalex.org/keywords/hla-matched-unrelated-donor","display_name":"HLA-matched unrelated donor","score":0.5929999947547913}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8485559821128845},{"id":"https://openalex.org/C2778684742","wikidata":"https://www.wikidata.org/wiki/Q2298283","display_name":"Melphalan","level":3,"score":0.7706499099731445},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.7591254711151123},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7481917142868042},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.7429487705230713},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5821326971054077},{"id":"https://openalex.org/C2777408962","wikidata":"https://www.wikidata.org/wiki/Q1128050","display_name":"Hematopoietic stem cell transplantation","level":3,"score":0.5213678479194641},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5187287926673889},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.504780650138855},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4740835428237915},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4069683253765106},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.35422033071517944},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.29159867763519287},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.23690080642700195}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v128.22.5885.5885","doi":"https://doi.org/10.1182/blood.v128.22.5885.5885","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.5885.5885","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2210596783","https://openalex.org/W2904085540","https://openalex.org/W2965741498","https://openalex.org/W2047682926","https://openalex.org/W2085715737","https://openalex.org/W2323202454","https://openalex.org/W1991268858","https://openalex.org/W2117648349","https://openalex.org/W2585135880","https://openalex.org/W2063142456"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Multiple":[2],"myeloma":[3,31,54,92,464],"remains":[4,21],"incurable":[5],"despite":[6],"impressive":[7],"array":[8],"of":[9,44,49,86,132,161,178,210,267,279,296,322,337,386,416,422,496,526,541,558],"available":[10],"novel":[11],"agents":[12],"and":[13,74,99,121,143,145,154,217,286,299,314,345,355,366,376,398,408,432,443,465],"therapeutic":[14],"strategies.":[15],"Allogeneic":[16],"hematopoietic":[17],"cell":[18,229],"transplantation":[19],"(HCT)":[20],"the":[22,176,208,417,434],"only":[23,184],"potentially":[24,438,458],"curative":[25,439],"option":[26,440],"for":[27,136,149,389,436,449,460],"patients":[28,55,93,108,223,260,288,445],"with":[29,264,276,426,462],"multiple":[30],"but":[32,180],"it":[33],"is":[34,469],"limited":[35],"by":[36,157],"its":[37],"toxicities.":[38],"We":[39],"previously":[40],"reported":[41],"initial":[42,65],"result":[43],"a":[45,82,158,265,277,382,466],"phase":[46,419],"2":[47,150,287,346,397,420],"study":[48,468],"upfront":[50,423,450],"allogeneic":[51,95,192,211,424],"HCT":[52,96,212,425],"in":[53],"achieving":[56,113],"at":[57,101,198,207,304,332,340,363,395],"least":[58],"very":[59],"good":[60],"partial":[61],"response":[62,119],"(VGPR)":[63],"after":[64,81,191],"therapy":[66,188],"(Nishihori,":[67],"et":[68],"al.":[69],"ASH":[70],"2013":[71],"abstract":[72],"3390)":[73],"here":[75],"we":[76],"report":[77],"more":[78],"mature":[79],"results":[80,415],"median":[83,196,266,278,383],"follow":[84,384],"up":[85,385],"3":[87,367,399],"years.":[88,204],"Methods:":[89],"Twenty":[90],"seven":[91],"received":[94,224],"between":[97],"01/2010":[98],"02/2015":[100],"Moffitt":[102],"Cancer":[103],"Center":[104],"(NCT":[105],"00948922).":[106],"Eligible":[107],"were":[109,307,348,369,401],"age":[110,197],"\u2264":[111],"60,":[112],"first":[114],"\u2265":[115],"VGPR":[116,214],"or":[117,126,236,252,256,498,528,543,560],"complete":[118],"(CR),":[120],"have":[122],"8/8":[123],"HLA-matched":[124,232,237],"related":[125,233],"unrelated":[127,238],"donors.":[128],"Conditioning":[129],"regimen":[130],"consisted":[131],"fludarabine":[133],"30":[134],"mg/m2":[135,148,164],"4":[137],"days":[138,151,285],"(days":[139,152],"-6,":[140],"-5,":[141],"-4,":[142],"-3)":[144,155],"melphalan":[146],"70":[147],"-4":[153],"followed":[156],"single":[159],"dose":[160],"bortezomib":[162],"1.3":[163],"on":[165,492,522,537,554],"day":[166,305,341],"-3":[167],"(Flu/Mel/Vel":[168],"regimen).":[169],"GVHD":[170,303,327],"prophylaxis":[171,244],"was":[172,189,200,213,245,274,328],"initially":[173],"left":[174],"to":[175,183,324,441],"discretion":[177],"physicians":[179],"later":[181],"modified":[182],"tacrolimus/methotrexate.":[185],"No":[186],"maintenance":[187],"prescribed":[190],"HCT.":[193],"Results:":[194],"The":[195,293,319,334,414],"transplant":[199],"50":[201],"(range,":[202,269,281],"25-58)":[203],"Disease":[205],"status":[206],"time":[209],"(n=17:":[215],"63%)":[216],"CR/stringent":[218],"CR":[219],"(n=10:":[220],"37%).":[221],"All":[222,259],"unmanipulated":[225],"peripheral":[226],"blood":[227],"stem":[228],"grafts":[230],"from":[231],"donors":[234,239],"(n=14)":[235],"(n=13).":[240],"Graft-versus-host":[241],"disease":[242],"(GVHD)":[243],"tacrolimus":[246],"plus":[247],"either":[248],"methotrexate":[249],"(n=19:":[250],"70%),":[251],"mycophenolate":[253],"mofetil":[254],"(n=4),":[255],"sirolimus":[257],"(n=4).":[258],"achieved":[261,275],"neutrophil":[262],"engraftment":[263,273],"15":[268],"11-19)":[270],"days.":[271],"Platelet":[272],"17":[280],"13":[282],"-":[283],"35)":[284],"did":[289],"not":[290],"recover":[291],"platelets.":[292],"cumulative":[294,320,335],"incidences":[295,336],"grades":[297,300],"II-IV":[298],"III-IV":[301],"acute":[302],"100":[306],"63.6%":[308],"(95%":[309],"confidence":[310],"interval":[311],"(CI):":[312],"43.1-81.1)":[313],"19.6%":[315],"(95%CI:":[316,330,350,353,357,371,374,378,403,406,410],"5.4-39.9),":[317],"respectively.":[318,359,380,412],"incidence":[321],"moderate":[323],"severe":[325],"chronic":[326],"56.4%":[329],"36.3-75.5)":[331],"1-year.":[333],"transplant-related":[338],"mortality":[339],"100,":[342],"1":[343],"year":[344],"years":[347,368,400],"7.4%":[349],"0.8-20.0),":[351],"11.1%":[352,356],"2.7-25.4),":[354,358],"Progression-free":[360],"survival":[361,393],"estimates":[362,394],"1,":[364,396],"2,":[365],"74.1%":[370],"53.2-86.7),":[372],"65.1%":[373,377],"43.3-80.2),":[375],"49.9-87.5),":[379],"With":[381],"39":[387],"months":[388],"surviving":[390],"patients,":[391],"overall":[392],"85%":[402],"64.9-94.1),":[404],"75.4%":[405],"52.6-88.3),":[407],"69.1%":[409],"53.8-93.5),":[411],"Conclusions:":[413],"this":[418],"trial":[421],"fludarabine/melphalan/bortezomib":[427],"(Flu/Mel/Vel)":[428],"conditioning":[429],"are":[430,447],"promising":[431],"provide":[433],"rationale":[435],"reasonable":[437],"younger":[442],"fit":[444],"who":[446],"eligible":[448],"intensive":[451],"consolidation":[452],"strategy.":[453],"This":[454],"approach":[455],"may":[456],"be":[457],"valuable":[459],"those":[461],"high-risk":[463],"multicenter":[467],"currently":[470],"being":[471],"conducted":[472],"(BMT":[473],"CTN":[474],"protocol":[475],"1302:NCT02440464).":[476],"Disclosures":[477],"Nishihori:":[478],"Novartis:":[479,506,565,571],"Research":[480,484,487,501,504,507,510,514,518,531,550,572,575],"Funding;":[481,488,502,505,508,511,515,551,573,576],"Signal":[482,516,548],"Genetics:":[483,517,549,569],"Funding.":[485,519],"Baz:Takeda/Millennium:":[486],"Celgene:":[489],"Honoraria,":[490],"Membership":[491,521,536,553],"an":[493,523,538,555],"entity's":[494,524,539,556],"Board":[495,525,540,557],"Directors":[497,527,542,559],"advisory":[499,529,544,561],"committees,":[500,530,545,562],"Merck:":[503],"Karyopharm:":[509],"Bristol-Myers":[512],"Squibb:":[513],"Shain:Celgene:":[520],"Funding,":[532],"Speakers":[533,546,563,566,579],"Bureau;":[534,547,564],"Amgen/Onyx:":[535,577],"Takeda/Millennium:":[552,574],"Bureau.":[567,580],"Alsina:Signal":[568],"Consultancy;":[570],"Consultancy,":[578]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2017-08-31T00:00:00"}